Cerebrospinal fluid brain specific proteins in relation to nitric oxide metabolites during relapse of multiple sclerosis

Abstract

This study investigated the cerebrospinal fluid (CSF) levels of ferritin, S100B as biomarkers for glial activation and NfH^SM135 — a biomarker of axonal damage — in relation to nitric oxide (NO) metabolites: nitrate and nitrite (NOx) during acute multiple sclerosis (MS) relapse. Thirty-four relapsing—remitting MS (RR-MS) patients during acute relapse and 12 controls were enrolled. Patients were assessed on Expanded Disability Status Scale (EDSS) and underwent lumbar puncture within two weeks following relapse. Twenty patients were available for further follow-up and were assessed on EDSS 6—8 weeks since the relapse onset. The CSF NOx (P < 0.0001), NfH^SM135 ( P = 0.01) and S100B (P = 0.009) but not ferritin (P > 0.05) were significantly raised in MS group. There was a significant correlation between CSF ferritin and S100B in RR-MS group (P = 0.004). CSF NOx did not correlate with S100B and ferritin in study groups. RR-MS patients with detectable NfH^SM135 levels had higher NOx compared with subjects having undetectable NfH^SM135 (P = 0.03). In the follow-up study, raised baseline levels of NOx (P = 0.016) or NfH^SM135 (P = 0.04) inversely correlated with the clinical recovery grade expressed as relative EDSS change between baseline and follow-up. In conclusion, NO metabolites were increased and because of their correlation with a biomarker of axonal degeneration (neurofilaments) and a measure for clinical disability (EDSS), relapse-related nitrosative stress is likely to be relevant to the development of sustained disability in an individual patient. Multiple Sclerosis 2008; 14: 59—66. http://msj.sagepub.com

Keywords

cerebrospinal fluid ferritin multiple sclerosis neurofilament nitric oxide NOx S100B

Get full access to this article

View all access options for this article.

References

Frohman EM , Racke MK , Raine CS Multiple sclerosis — the plaque and its pathogenesis. N Engl J Med 2006; 354: 942—55.

Link H. The cytokine storm in multiple sclerosis. Mult Scler 1998; 4: 12—5.

Smith KJ , Lassmann H. The role of nitric oxide in multiple sclerosis. Lancet Neurol 2002; 1: 232—41.

Rejdak K. , Eikelenboom MJ , Petzold A. , Thompson EJ , Stelmasiak Z. , Lazeron RH et al. CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis. Neurology 2004; 63: 1439—45.

Petzold A. , Eikelenboom MJ , Gveric D. , Keir G. , Chapman M. , Lazeron RH et al. Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations. Brain 2002; 125: 1462—73.

Petzold A. Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J Neurol Sci 2005; 233: 183—98.

Petzold A. , Rejdak K. , Plant G. Axonal degeneration and inflammation in acute optic neuritis. J Neurol Neurosurg Psychiatry 2004; 75: 1178—80.

McDonald WI , Compston A. , Edan G. , Goodkin D. , Hartung HP , Lublin FD et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121—27.

Kurtzke JF Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444—52.

10.

Miranda KM , Espey MG , Wink DA A rapid, simple spectrophotometric method for simultaneous detection of nitrate and nitrite. Nitric Oxide 2001; 5: 62—71.

11.

Rejdak K. , Petzold A. , Sharpe MA , Smith M. , Keir G. , Stelmasiak Z. et al. Serum and urine nitrate and nitrite are not reliable indicators of intrathecal nitric oxide production in acute brain injury. J Neurol Sci 2003; 208: 1—7.

12.

Keir G. , Tasdemir N. , Thompson EJ Cerebrospinal fluid ferritin in brain necrosis: evidence for local synthesis . Clin Chim Acta 1993; 216: 153—66.

13.

Green AJ , Keir G. , Thompson EJ A specific and sensitive ELISA for measuring S-100b in cerebrospinal fluid . J Immunol Methods 1997; 205: 35—41.

14.

Petzold A. , Keir G. , Green AJ , Giovannoni G. , Thompson EJ A specific ELISA for measuring neurofilament heavy chain phosphoforms. J Immunol Methods 2003; 278: 179—90.

15.

Lim ET , Grant D. , Pashenkov M. , Keir G. , Thompson EJ , Soderstrom M. et al. Cerebrospinal fluid levels of brain specific proteins in optic neuritis. Mult Scler 2004; 10: 261—5.

16.

Malmestrom C. , Haghighi S. , Rosengren L. , Andersen O. , Lycke J. Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology 2003; 61: 1720—5.

17.

Norgren N. , Sundstrom P. , Svenningsson A. , Rosengren L. , Stigbrand T. , Gunnarsson M. Neurofilament and glial fibrillary acidic protein in multiple sclerosis. Neurology 2004; 63: 1586—90.

18.

Brettschneider J. , Petzold A. , Junker A. , Tumani H. Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis. Mult Scler 2006; 12: 143—8.

19.

Petzold A. , Eikelenboom MJ , Keir G. , Grant D. , Lazeron RH , Polman CH et al. Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study. J Neurol Neurosurg Psychiatry 2005; 76: 206—11.

20.

Kuhlmann T. , Lingfeld G. , Bitsch A. , Schuchardt J. , Bruck W. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 2002; 125: 2202—12.

21.

Bo L. , Dawson TM , Wesselingh S. , Mork S. , Choi S. , Kong PA et al. Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains. Ann Neurol 1994 ; 36: 778—86.

22.

Oleszak EL , Zaczynska E. , Bhattacharjee M. , Butunoi C. , Legido A. , Katsetos CD Inducible nitric oxide synthase and nitrotyrosine are found in monocytes/macrophages and/or astrocytes in acute, but not in chronic, multiple sclerosis. Clin Diagn Lab Immunol 1998; 5: 438—45.

23.

Liu JS , Zhao ML , Brosnan CF , Lee SC Expression of inducible nitric oxide synthase and nitrotyrosine in multiple sclerosis lesions. Am J Pathol 2001; 158: 2057—66.

24.

Hill KE , Zollinger LV , Watt HE , Carlson NG , Rose JW Inducible nitric oxide synthase in chronic active multiple sclerosis plaques: distribution, cellular expression and association with myelin damage. J Neuroimmunol 2004; 151: 171—9.

25.

Johnson AW , Land JM , Thompson EJ , Bolanos JP , Clark JB , Heales SJ Evidence for increased nitric oxide production in multiple sclerosis. J Neurol Neurosurg Psychiatry 1995; 58: 107.

26.

Cross AH , Manning PT , Keeling RM , Schmidt RE , Misko TP Peroxynitrite formation within the central nervous system in active multiple sclerosis. J Neuroimmunol 1998; 88: 45—56.

27.

Giovannoni G. Cerebrospinal fluid and serum nitric oxide metabolites in patients with multiple sclerosis. Mult Scler 1998; 4: 27—30.

28.

Brundin L. , Morcos E. , Olsson T. , Wiklund NP , Andersson M. Increased intrathecal nitric oxide formation in multiple sclerosis; cerebrospinal fluid nitrite as activity marker. Eur J Neurol 1999; 6: 585—90.

29.

Svenningsson A. , Petersson AS , Andersen O. , Hansson GK Nitric oxide metabolites in CSF of patients with MS are related to clinical disease course. Neurology 1999; 53: 1880—2.

30.

Peltola J. , Ukkonen M. , Moilanen E. , Elovaara I. Increased nitric oxide products in CSF in primary progressive MS may reflect brain atrophy. Neurology 2001; 57: 895—6.

31.

Moncada S. , Bolanos JP Nitric oxide, cell bioenergetics and neurodegeneration. J Neurochem 2006; 97: 1676—89.

32.

Okuda Y. , Sakoda S. , Fujimura H. , Yanagihara T. Nitric oxide via an inducible isoform of nitric oxide synthase is a possible factor to eliminate inflammatory cells from the central nervous system of mice with experimental allergic encephalomyelitis. J Neuroimmunol 1997; 73: 107—16.

33.

Kahl KG , Schmidt HH , Jung S. , Sherman P. , Toyka KV , Zielasek J. Experimental autoimmune encephalomyelitis in mice with a targeted deletion of the inducible nitric oxide synthase gene: increased T-helper 1 response . Neurosci Lett 2004; 358: 58—62.

34.

Dalton DK , Wittmer S. Nitric-oxide-dependent and independent mechanisms of protection from CNS inflammation during Th1-mediated autoimmunity: evidence from EAE in iNOS KO mice. J Neuroimmunol 2005; 160: 110—21.

35.

Staykova MA , Paridaen JT , Cowden WB , Willenborg DO Nitric oxide contributes to resistance of the Brown Norway rat to experimental autoimmune encephalomyelitis. Am J Pathol 2005; 166: 147—57.

36.

Danilov AI , Jagodic M. , Wiklund NP , Olsson T. , Brundin L. Effects of long term NOS inhibition on disease and the immune system in MOG induced EAE. Nitric Oxide 2005; 13: 188—95.

37.

Waxman SG Nitric oxide and the axonal death cascade. Ann Neurol 2003; 53: 150—3.

38.

Massaro AR , Michetti F. , Laudisio A. , Bergonzi P. Myelin basic protein and S-100 antigen in cerebrospinal fluid of patients with multiple sclerosis in the acute phase. Ital J Neurol Sci 1985; 6: 53—6.

39.

Donato R. Intracellular and extracellular roles of S100 proteins. Microsc Res Tech 2003; 60: 540—51.

40.

Van Eldik LJ , Wainwright MS The Janus face of glial-derived S100B: beneficial and detrimental functions in the brain. Restor Neurol Neurosci 2003; 21: 97—108.

41.

Rejdak K. , Petzold A. , Kocki T. , Kurzepa J. , Grieb P. , Turski WA et al. Astrocytic activation in relation to inflammatory markers during clinical exacerbation of relapsing-remitting multiple sclerosis. J Neural Transm 2007; in press.

42.

Hulet SW , Powers S. , Connor JR Distribution of transferrin and ferritin binding in normal and multiple sclerotic human brains. J Neurol Sci 1999; 165: 48—55.

43.

Regan RF , Kumar N. , Gao F. , Guo Y. Ferritin induction protects cortical astrocytes from heme-mediated oxidative injury. Neuroscience 2002; 113: 985—94.

44.

LeVine SM , Lynch SG , Ou CN , Wulser MJ , Tam E. , Boo N. Ferritin, transferrin and iron concentrations in the cerebrospinal fluid of multiple sclerosis patients. Brain Res 1999; 821: 511—5.

45.

Recalcati S. , Taramelli D. , Conte D. , Cairo G. Nitric oxide-mediated induction of ferritin synthesis in J774 macrophages by inflammatory cytokines: role of selective iron regulatory protein-2 downregulation . Blood 1998; 91: 1059—66.

46.

Kim S. , Ponka P. Effects of interferon-gamma and lipopolysaccharide on macrophage iron metabolism are mediated by nitric oxide-induced degradation of iron regulatory protein 2. J Biol Chem 2000; 275: 6220—6.

47.

Stolzing A. , Wengner A. , Grune T. Degradation of oxidized extracellular proteins by microglia. Arch Biochem Biophys 2002; 400: 171—9.

48.

Mehlhase J. , Sandig G. , Pantopoulos K. , Grune T. Oxidation-induced ferritin turnover in microglial cells: role of proteasome. Free Radic Biol Med 2005; 38: 276—85.

49.

Ernst A. , Stolzing A. , Sandig G. , Grune T. Protein oxidation and the degradation of oxidized proteins in the rat oligodendrocyte cell line OLN 93-antioxidative effect of the intracellular spin trapping agent PBN. Brain Res Mol Brain Res 2004; 122: 126—32.

50.

Minagar A. , Shapshak P. , Fujimura R. , Ownby R. , Heyes M. , Eisdorfer C. The role of macrophage/ microglia and astrocytes in the pathogenesis of three neurologic disorders: HIV-associated dementia, Alzheimer disease, and multiple sclerosis. J Neurol Sci 2002; 202: 13—23.

51.

Tanuma N. , Sakuma H. , Sasaki A. , Matsumoto Y. Chemokine expression by astrocytes plays a role in microglia/macrophage activation and subsequent neurodegeneration in secondary progressive multiple sclerosis . Acta Neuropathol (Berl) 2006; 112: 195—204.